Founded by leading cancer genomics researchers and clinicians, Predicta is a precision oncology company developing novel diagnostic and therapeutic products. The company's non-invasive diagnostics initially focus on multiple myeloma and evaluate patients' immune system cells, equipping physicians with the unique ability to determine the likelihood of a patient responding to immunotherapies. Leveraging extensive genomic and transcriptomic patient data, Predicta is also building a one-of-a-kind clinical database for identifying new therapeutic targets.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/16/24	$5,200,000	Seed	Illumina Ventures Oetgen Family The American Cancer Society Bright Edge The Engine Time Boost Capital	undisclosed
10/01/25	$23,400,000	Series A	ACS BrightEdge Binney Street Capital Engine Ventures Illumina Ventures Lightchain Capital Mass General Brigham Ventures Myeloma Solutions Fund	undisclosed